Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U01 Substudy 01F in previously treated KRAS G12C-mutated advanced or metastatic non-squamous NSCLC
CTR20261379Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of calderasib in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Apr 2026; status: active.
02
Drugs
calderasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20261379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261379.